Demodex folliculitis (off-label use): Oral: 200 mcg/kg once weekly for 2 doses (Ref).
Hookworm-related cutaneous larva migrans (off-label use): Oral: 200 mcg/kg once daily for 1 or 2 days (Ref).
Lice, refractory (off-label use):
Note: Reserve for patients with an insufficient response to topical therapy (Ref). Optimal dose, dosing interval, and frequency are uncertain (Ref).
Pediculus capitis: Oral: 200 mcg/kg once weekly for 2 doses (Ref); some experts suggest 400 mcg/kg once weekly for 2 doses (Ref).
Pediculosis pubis: Oral: 200 mcg/kg once weekly for 2 doses (Ref); some experts suggest 250 mcg/kg once, with a repeat dose in 7 to 14 days (Ref).
Mansonella infection (off-label use):
Note: For individuals from Loa loa–endemic areas, rule out co-infection prior to ivermectin administration to avoid life-threatening encephalopathy (Ref).
Mansonella ozzardi: Oral: 150 mcg/kg as a single dose (Ref).
Mansonella streptocerca infection (alternative agent): Oral: 150 mcg/kg as a single dose (Ref).
Onchocerciasis:
Note: For individuals from Loa loa–endemic areas, rule out co-infection prior to ivermectin administration to avoid life-threatening encephalopathy (Ref).
Oral: 150 mcg/kg once; repeat dose every 3 to 6 months until asymptomatic (Ref). For patients outside endemic areas or in areas with low transmission, doxycycline therapy is initiated 1 week after the initial ivermectin dose (Ref).
Scabies (off-label use):
Note: For cohabitants or other individuals who have had prolonged skin-to-skin contact within the previous 6 weeks, simultaneous treatment is recommended (Ref).
Classic scabies, treatment: Oral: 200 mcg/kg once; repeat dose in 7 to 14 days (Ref).
Crusted scabies, treatment: Oral: 200 mcg/kg once daily in combination with permethrin for 3, 5, or 7 nonconsecutive days depending on infection severity (eg, for 3 days: give on days 1, 2, and 8; for 5 days: give on days 1, 2, 8, 9, and 15; for 7 days: give on days 1, 2, 8, 9, 15, 22, and 29) (Ref).
Strongyloidiasis:
Note: For individuals from Loa loa–endemic areas, rule out co-infection prior to ivermectin administration to avoid life-threatening encephalopathy (Ref).
Uncomplicated infection:
Patients who are immunocompetent: Oral: 200 mcg/kg once daily for 1 or 2 days (Ref).
Patients who are immunocompromised: Oral: 200 mcg/kg once daily for 2 days; repeat dosing regimen in 2 weeks (Ref).
Severe, disseminated infection: Oral: 200 mcg/kg once daily until symptoms have resolved and stool and/or sputum examination is negative for ≥2 weeks (Ref). Some experts suggest switching to an alternative approach for patients who are immunocompromised or critically ill with persistently positive (eg, ≥3 days) stool examination (Ref). For patients with persistent immunosuppression after clinical improvement, some experts use suppressive ivermectin 200 mcg/kg once monthly for ≥6 months (Ref).
Trichuriasis (whipworm) (alternative agent) (off-label use): Oral: 600 mcg/kg once daily for 3 days in combination with albendazole (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (<1% excreted in the urine) (Ref).
Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (highly protein bound; large Vd): No supplemental dose or dosage adjustment necessary (Ref).
Peritoneal dialysis: Unlikely to be significantly dialyzed (highly protein bound; large Vd): No dosage adjustment necessary (Ref).
CRRT: No dosage adjustment necessary (Ref).
PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).
There are no dosage adjustments provided in manufacturer’s labeling.
Refer to adult dosing.
(For additional information see "Ivermectin (systemic): Pediatric drug information")
Dosage guidance:
Safety: For individuals from Loa loa-endemic areas, rule out coinfection prior to ivermectin administration to avoid life-threatening encephalopathy (Ref).
Dosing: Description of ivermectin use in infants and children weighing <15 kg is limited due to theoretical risk for CNS adverse events, however it has been used in this population for a variety of indications with no reports of serious adverse events (Ref). Following the indication-specific dosing information are weight-band dosing tables to assist with calculation and rounding of doses.
Ascariasis (Ascaris lumbricoides); roundworm (alternative agent): Limited data available: Children ≥15 kg and Adolescents: Oral: 150 to 200 mcg/kg/dose as a single dose (Ref).
Gnathostomiasis, cutaneous: Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose once daily for 2 days (Ref).
Hookworm-related cutaneous larva migrans: Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg as a single dose (Ref).
Lice (alternative agent): Limited data available: Note: Ivermectin is not ovicidal; therefore, repeat doses are necessary to eradicate infestation:
Head lice: Children ≥15 kg and Adolescents: Oral: 200 to 400 mcg/kg/dose for 2 doses administered 9 to 10 days apart. Dosing at the higher end of the range (ie, 400 mcg/kg/dose) may result in fewer treatment failures (Ref).
Pubic lice: Children ≥15 kg and Adolescents: Oral: 250 mcg/kg/dose for 2 doses administered 7 to 14 days apart (Ref).
Onchocerciasis (Onchocerca volvulus); river blindness:
Children ≥15 kg and Adolescents: Oral: 150 mcg/kg/dose every 3 to 6 months until asymptomatic (Ref). Ivermectin is only effective against microfilariae; if treatment of macrofilariae is desired, doxycycline may be initiated 1 week after ivermectin treatment (Ref).
Scabies: Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose for 2 doses administered at 7 to 14 days apart (Ref).
Strongyloidiasis:
Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose once daily for 1 to 2 days. Patients with hyperinfection and disseminated disease may need prolonged or repeated treatment (eg, daily treatment until stool and/or sputum exams are negative for 2 weeks) (Ref).
Trichuriasis ( Trichuris trichiura); whipworm: Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose once daily for 3 days (Ref).
Weight-band dosing: Weight-band dosing tables are provided to assist with calculation and rounding of doses; refer to indication-specific dosing for details.
Patient Weight |
Single Oral Dose |
---|---|
15 to 25 kg |
3 mg |
26 to 44 kg |
6 mg |
45 to 64 kg |
9 mg |
65 to 84 kg |
12 mg |
Patient Weight |
Single Oral Dose |
---|---|
15 to 24 kg |
3 mg |
25 to 35 kg |
6 mg |
36 to 50 kg |
9 mg |
51 to 65 kg |
12 mg |
66 to 79 kg |
15 mg |
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
CNS effects including neurotoxicity (eg, ataxia, confusion, disorientation, encephalopathy, impaired consciousness [including coma], stupor, tremor) and central nervous system depression with subsequent breathing difficulties, have rarely been reported in humans, but are well known to occur in animals (Ref). Theoretical risk for CNS effects in infants and young children due to immature blood-brain barrier has been extrapolated from animal data and has minimized use in patients <15 kg. Existing data in younger pediatric patients are limited, with recent evaluations describing ivermectin use in patients <15 kg for a variety of indications with no reports of serious adverse events (Ref).
Mechanism: CNS effects occur when ivermectin crosses the blood-brain barrier into the spinal cord, midbrain or cerebrum and blocks important neuronal transmission that involves glutamate or gamma-amino butyric acid (Ref). In infants and young children, it has been proposed that ivermectin may cross the immature blood-brain barrier, resulting in CNS toxicity (Ref). In patients with a well-developed blood-brain barrier, the neurological adverse effects of ivermectin are thought to occur when the ATP-binding cassette subfamily B member 1 (ABCB1) transporter (also known as P-glycoprotein) is altered and fails to prevent the uptake of ivermectin into the brain (Ref).
Onset: Rapid; typically occurs within hours of dosing, although has also been described as late as 7 days after administration (Ref).
Risk factors:
• Immature blood-brain barrier (Ref)
• Body weight <15 kg as a surrogate marker for an immature blood-brain barrier (Ref)
• Mutation in ABCB1 (P-glycoprotein) transporter (Ref)
A variety of delayed hypersensitivity reactions, ranging from skin rash to severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms have been reported with ivermectin use (Ref).
Mechanism: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including rashes (often maculopapular) and SCARs are T-cell-mediated (Ref).
Onset: Delayed hypersensitivity reactions: Varied. SCARs usually occur within 1 to 8 weeks after initiation (Ref), although cases associated with ivermectin have been reported within 3 days after receiving a single dose (Ref).
Ivermectin may cause an immunologic post-treatment reaction, also known as a Mazzoti reaction, which is associated with pruritus, skin rash, fever, fatigue, lymphadenopathy, arthralgia, tachycardia, hypotension (including orthostatic hypotension), edema, and abdominal pain (Ref). Most cases have been reported in association with the treatment of onchocerciasis, but cases have also been reported in association with the treatment of other infections (eg, scabies) (Ref). Symptoms are mostly mild and usually resolve in 4 days; however, cases of coma and death have been reported, although these deaths are often attributed to Loa loa-associated encephalopathy (Ref). Serious Mazzoti reactions are estimated to occur in 19% to 81% of patients exposed to ivermectin for the treatment of filarial parasites, which is disproportionality more than other antinematodal drugs (Ref).
Mechanism: Non–dose-related; immunologic. Ivermectin exerts a strong microfilaricidal effect on filariae, leading to a destruction of microfilariae. In patients with high densities of microfilariae in the skin or blood, this may induce complex inflammatory reactions resulting in local tissue damage and degradation of host structures (Ref).
Onset: Varied; within 1 to 7 days of therapy initiation (Ref).
Risk factors:
• High densities of microfilariae (ie, the larval stages of the filarial parasites) (Ref)
• Treatment of filarial parasites (Ref)
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
≥10%: Miscellaneous: Mazzotti reaction (associated with onchocerciasis: pruritus: 28%; fever: 23%; skin edema, papular rash, pustular rash, and urticaria: ≤23%; arthralgia and synovitis: ≤9%; lymphadenitis [axillary node: 4% to 11%, cervical node: 1% to 5%, inguinal node: 13% to 14%, other lymph node: 2% to 3%])
1% to 10%:
Cardiovascular: Orthostatic hypotension (1%), peripheral edema (3%), tachycardia (4%)
Dermatologic: Pruritus (associated with strongyloidiasis: 3%)
Gastrointestinal: Diarrhea (2%), nausea (2%)
Hematologic & oncologic: Decreased white blood cell count (3%), eosinophilia (3%), increased hemoglobin (1%)
Hepatic: Increased serum alanine aminotransferase (2%), increased serum aspartate aminotransferase (2%)
Hypersensitivity: Facial edema (1%)
Nervous system: Dizziness (3%)
Ophthalmic: Inflammation of limbus of eyes (4% to 6%), punctate cataract (1% to 2%)
<1%:
Dermatologic: Skin rash, urticaria (associated with strongyloidiasis)
Gastrointestinal: Abdominal pain, anorexia, constipation, vomiting
Hematologic & oncologic: Anemia, leukopenia
Nervous system: Asthenia, drowsiness, fatigue, headache, tremor, vertigo
Neuromuscular & skeletal: Myalgia
Ophthalmic: Vision loss
Frequency not defined:
Cardiovascular: Chest discomfort
Gastrointestinal: Abdominal distention
Postmarketing:
Cardiovascular: Hypotension
Dermatologic: Stevens-Johnson syndrome (Oshikoya 2020), toxic epidermal necrolysis (Oshikoya 2020)
Hepatic: Hepatitis (Veit 2006), increased liver enzymes, increased serum bilirubin
Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Kerneuzet 2018)
Nervous system: Central nervous system depression (Chandler 2018), neurotoxicity (including ataxia, confusion, disorientation, encephalopathy, impaired consciousness [including coma], stupor) (Baudou 2020; Chandler 2018), seizure (Chandler 2018)
Ophthalmic: Abnormal sensation in eyes, anterior uveitis, chorioretinitis (including choroiditis), conjunctival hemorrhage, conjunctivitis, diplopia (Campillo 2021), eyelid edema, keratitis
Respiratory: Exacerbation of asthma
Hypersensitivity to ivermectin or any component of the formulation
Special populations:
• Immunocompromised patients: Repeated treatment may be required in immunocompromised patients (eg, HIV); control of extraintestinal strongyloidiasis may necessitate suppressive (once monthly) therapy.
Other warnings/precautions:
• Appropriate use: Onchocerca volvulus: Ivermectin has no activity against adult O. volvulus parasites. L. loa: Ivermectin is not active against adult worms.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral:
Stromectol: 3 mg
Generic: 3 mg
Yes
Tablets (Ivermectin Oral)
3 mg (per each): $4.97
Tablets (Stromectol Oral)
3 mg (per each): $5.58
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: Administer on an empty stomach with water (manufacturer’s labeling). Some experts recommend administering with food to increase absorption (Ref).
Oral: The manufacturer recommends administration on an empty stomach with water. However, some experts recommend administering with food to increase absorption; administration with a high-fat meal as compared to fasted increased bioavailability ~2.5 times in healthy volunteers (Ref).
Onchocerciasis: Treatment of onchocerciasis due to the immature form of Onchocerca volvulus.
Limitations of use: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules, which are infrequently palpable. Surgical excision may be considered since removal of these nodules will eliminate the microfilariae-producing adult parasites.
Strongyloidiasis: Treatment of intestinal (eg, nondisseminated) strongyloidiasis due to Strongyloides stercoralis.
Ascariasis; Demodex folliculitis; Gnathostomiasis, cutaneous; Hookworm-related cutaneous larva migrans; Lice, refractory; Mansonella infection; Scabies; Trichuriasis
KIDs List: Ivermectin (systemic), when used in infants <1 year of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of encephalopathy (weak recommendation; low quality of evidence) (PPA [Meyers 2020]).
Substrate of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination
Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination
Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination
Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy
Bioavailability appears to be increased with food, but the extent of the interaction is uncertain. When administered following a high-fat meal, bioavailability has been shown to increase 1.18- to 2.57-fold with a wide range of doses studied (6 to 30 mg) (Duthaler 2020; Guzzo 2002; Miyajima 2016). Management: The manufacturer recommends to administer on an empty stomach, although some experts recommend administering with food to increase absorption (CDC [Workowski 2021]; Currie 2010).
Evaluate pregnancy status prior to use in patients who may become pregnant; patients arriving as refugees from specific countries should not be given ivermectin for the presumptive treatment of intestinal parasites without a reliable history of their last menstrual period (CDC 2019a).
Outcome information following maternal use of ivermectin during pregnancy is primarily limited to inadvertent exposure during mass treatment programs (Chippaux 1993; Gyapong 2003; Ndyomugyenyi 2008; Nicolas 2020; Pacqué 1990; Westlake 2020).
The decision to use ivermectin during pregnancy should consider the specific indication (eg, onchocerciasis or Strongyloides infection) and the risk of disease progression in the absence of treatment (CDC 2021; CDC 2022) Although use in pregnancy is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in pregnant patients (CDC [Workowski 2021]).
Ivermectin is present in breast milk.
Peak ivermectin breast milk concentrations generally occurred between 4 hours (n=2) and 6 hours (n=2) after a single maternal dose; although the peak breast milk concentration occurred at 12 hours in one patient (Ogbuokiri 1994; Rodari 2020).
The decision to use ivermectin in a patient who is breastfeeding should consider the specific indication (eg, onchocerciasis or Strongyloides infection) and the risk of disease progression in the absence of treatment (CDC 2021; CDC 2022). Although use is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in patients who are breastfeeding (CDC [Workowski 2021]). Breastfeeding patients arriving as refugees from specific countries should not be given ivermectin for the presumptive treatment of intestinal parasites during their first week postpartum (CDC 2019a).
Skin and eye microfilarial counts, periodic ophthalmologic exams; follow up stool examinations; signs and symptoms of neurotoxicity.
Ivermectin is a semisynthetic anthelminthic agent; it binds selectively and with strong affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, and death of the parasite.
Absorption: Well absorbed in the fasting state (Baraka 1996; Edwards 1988; Okonkwo 1993); may be increased with a high-fat meal (Duthaler 2020; Guzzo 2002; Miyajima 2013).
Distribution: Vd:
Children 2 to 5 years: Median range: 7.46 to 8.26 L/kg (Schulz 2019).
Children 6 to 12 years: Median range: 8.58 to 10.4 L/kg (Schulz 2019).
Adults: 3.1 to 3.5 L/kg in healthy volunteers; mean 9.9 L/kg (range: 6.9 to 15.3 L/kg) in patients with onchocerciasis; high concentration in the liver and adipose tissue; does not readily cross the blood-brain barrier (Gonzalez Canga 2008; Okonkwo 1993).
Protein binding: ~93% primarily to albumin (Gonzalez Canga 2008).
Metabolism: Hepatic via CYP3A4 (major), CYP2D6 (minor), and CYP2E1 (minor).
Half-life elimination:
Children 2 to 5 years: Median range: 16.3 to 17.3 hours (Schulz 2019).
Children 6 to 12 years: Median range: 18.1 to 19.1 hours (Schulz 2019).
Adults: 18 hours.
Time to peak, serum: ~4 hours.
Excretion: Feces; urine (<1%).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟